Dr. Velazquez-Martin serves as our Senior Vice President of Clinical Research and Translational Medicine and is an ophthalmologist and retinal specialist. Previously, Dr Velazquez-Martin was head of ophthalmology global medical affairs for Bayer in Europe, Canada, and Latin America with a focus on Bayer’s ex-U.S. Eylea franchise. His emphasis was on scientific differentiation of Eylea with phase 3 and phase 4 clinical studies design, interpretation and communication. Dr. Velazquez-Martin contributed to the dramatic growth of Eylea revenue and market share on a local, regional, and global basis. In his role at Kodiak, Dr. Velazquez-Martin is responsible for generating scientific and clinical data to help differentiate and profile our therapeutic candidates and ABC Platform versus the approved agents Eylea and Lucentis as well as versus other retinal medicines in development. Dr. Velazquez-Martin earned his M.D. from the National Autonomous University of Mexico. Upon completion of a residency in ophthalmology and obtaining an ophthalmology surgeon certification, he completed a two-year fellowship in retina surgery, followed by an ocular oncology fellowship at the University of Toronto. During his tenure at the Princess Margaret Cancer Centre in Toronto, he led the ophthalmic evaluation of patients in phase 1 and phase 2 clinical trials of novel cancer agents.
Pablo Velazquez-Martin, M.D.
Senior Vice President, Clinical Research and Translational Medicine